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Abstract
Background: The nuclear receptor liver X receptor (LXR) exerts transcriptional control over lipid metabolism and
inflammatory response in cells of the myeloid lineage, suggesting that LXR may be a potential target in a number
of chronic neuroinflammatory and neurodegenerative diseases where persistent microglial activation has been
implicated in the pathogenesis.
Methods: The effect of LXR activation on microglia and central nervous system (CNS) inflammation was studied
using a synthetic LXR agonist in cultured microglia, a microglial cell line and experimental allergic
encephalomyelitis (EAE), an animal model of CNS inflammation.
Results: LXR activation inhibited nitric oxide synthase 2, inducible (Nos2) expression and nitric oxide production in
lipopolysaccharide (LPS)-stimulated microglia. Inhibition of microglial activation in response to interferon-γ was less
reliable. In LPS-stimulated cells, LXR activation did not inhibit nuclear translocation of NF-kappaB1 p50. Instead,
LXR-dependent Nos2 repression was associated with inhibition of histone 4 acetylation and inhibition of NF-kappaB1
p50 binding at the Nos2 promoter. Histone acetylation and NF-kappaB1 p50 binding were mechanistically linked, and
histone deacetylase (HDAC) activity appeared to be important for LXR-dependent transcriptional repression of Nos2.
Analysis of CNS gene expression in animals undergoing EAE showed that the expressions of Lxr and LXR-dependent
genes were downregulated during CNS inflammation. Nevertheless, administration of LXR agonist GW3965 during the
effector phase of EAE delayed the onset of clinical disease and reversed the diminished expression of LXR-dependent
reverse cholesterol transport genes. However, the CNS expressions of Nos2 and other inflammatory genes were
not significantly inhibited by LXR activation in EAE, and clinical disease severity was comparable to vehicle controls at
later time points in LXR agonist treated animals.
Conclusions: LXR can be targeted to modulate microglial activation. LXR-dependent repression of inflammatory genes
may be stimulus-dependent and impaired by HDAC inhibition. Endogenous LXR activity does not appear to modulate
CNS inflammation, but LXR activity can be partially restored in the CNS by administration of exogenous LXR agonist
with an impact on clinical disease severity at early, but not late, time points in EAE.
Keywords: Liver X receptor, Microglia, Inflammation, HDAC, NF-kappaB, Central nervous system, Experimental allergic
encephalomyelitis
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Background
Microglia are resident innate immune cells of the CNS
and contribute to CNS inflammation and repair through
multiple functions including scavenging, phagocytosis,
antigen presentation and production of reactive oxygen/
nitrogen species, cytokines and neurotropic factors [1].
Reactive microgliosis, or a state of persistent microglial
activation, has been implicated in the pathogenesis of a
number of neuroinflammatory and neurodegenerative
diseases including multiple sclerosis, Parkinson disease
and Alzheimer disease [2]. The production of excess reactive oxygen and reactive nitrogen species by activated
microglia is thought to contribute to neurodegeneration
by way of oxidative stress [3]. Inhibiting microglial activation or function has the potential to ameliorate neuroinflammatory and neurodegenerative disorders [4,5].
Defining the signals that control microglial activation,
therefore, has important implications for modulating
neuroinflammatory and neurodegenerative processes.
The liver X receptor (LXR) is an oxysterol-activated
nuclear receptor [6]. Together with retinoid X receptor
(RXR), with which LXR forms an obligate heterodimer,
LXR controls gene transcription by modulating the function of nuclear receptor corepressor (NCoR) and nuclear
receptor coactivator (NCoA) complexes [7]. LXR is
known to control the expression of genes involved in reverse cholesterol transport such as Abca1, Abcg1, Apoa1,
Apoe and Cyp7a1 [8,9]. In cells of the myeloid lineage,
LXR has also been shown to control inflammatory responses by transcriptional repression of a number of
genes including Nos2, Cox2 and Il6 [10]. Thus, LXR is
one among a number of biological signal pathways that
link lipid metabolism and inflammation [11]. Previous
studies have shown that activation of LXR by oxysterols
inhibits proinflammatory responses in cultures of microglia and astrocytes, suggesting that the LXR pathway
might serve a compensatory antiinflammatory function
in response to oxidative stress [12,13]. In addition, previous
studies have shown that LXR agonists reduced the severity
of experimental allergic encephalomyelitis (EAE), an animal
model of neuroinflammation, during its induction phase by
an immunomodulatory effect on T helper lymphocyte differentiation [14,15].
Several questions remain regarding the role of LXR in
CNS inflammation. It is unknown whether or not endogenous activation of LXR in the CNS functions to
modulate the course of CNS inflammation. A related
question is whether or not targeting LXR confers protection in the setting of already established CNS inflammation, independent of its immunomodulatory effects on
peripheral lymphocytes. We examined LXR function and
the mechanism of transcriptional repression in cultured
microglia as well as the effect of LXR activation during
CNS inflammation.
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Methods
Reagents

Culture media, fetal calf serum, all media supplements,
buffered solutions, Griess reagent kit and RNAi Max
were from Life Technologies (Carlsbad, CA). GW3965
and fluorobexarotene were from R & D Systems
(Minneapolis, MN). LPS, trichostatin A, C646 and
TMB peroxidase substrate were from Sigma-Aldrich
(St. Louis, MO).
Primary murine microglial cultures

Timed-pregnant ICR mice were purchased form Harlan
(Indianapolis, IN). Primary microglia-enriched cultures
were prepared from whole brains of 1- to 2-day-old ICR
pups using a previously described protocol [16]. Briefly,
following removal of meninges and blood vessels, brains
were mechanically dissociated by trituration then seeded
in 150-cm3 flasks in supplemented DMEM/F12 media
containing 10% fetal calf serum (4 to 5 brains per flask).
Media were replaced at day 3 and 7 of culture. Microglia
were shaken off at days 14 and 21 of culture and replated at 1 × 105 cells/well in DMEM containing 2% fetal
calf serum. Cells were treated 24 h after re-plating.
Real-time reverse transcription-polymerase chain reaction
(RT-PCR)

Real-time RT-PCR analyses of Abca1, Abcg1, Apoa1,
Nos2, Il1b, Il6, Lxra, Lxrb and Tnf were performed using
commercially available primer and probes sets and Taqman
RNA-to-CT 1-Step Kit (Life Technologies, Carlsbad, CA)
according to the manufacturer’s protocol. Total RNA was
extracted using RNeasy Mini Kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Relative quantitation of mRNA was performed using the comparative
threshold (delta delta CT) method [17] using Actb as endogenous control.
Cytokine ELISA

Interleukin-1β (IL-1β) and tumor necrosis factor (TNF)
in conditioned media were measured using the antibodies and reference standards contained in R & D Systems DuoSet ELISA kits (R & D, Minneapolis, MN)
according to the manufacturer’s protocol. Test samples
and reference standards were incubated for 2 h in wells
that had been coated overnight with 0.8 μg/ml goat antimouse TNF or 4.0 μg/ml rat anti-mouse IL-1β capture
antibodies in phosphate-buffered saline (PBS) and blocked
for 1 h with 300 μl of 1% w/v bovine serum albumin (BSA)
in PBS. Captured cytokines were detected with biotinylated
goat anti-mouse TNF or IL-1β detection antibodies, visualized by incubation for 30 min with streptavidin-HRP
followed by timed incubation with TMB peroxidase substrate. The enzyme reactions were quenched by addition of
2 N H2SO4, and the absorbance of the resulting solutions
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was measured using a microplate spectrophotometer
(BioTek, Winnoski, VT). The cytokine concentration in
each test sample was calculated by the instrument software using the formula of the four-parameter best-fit
curve to the standards.
Griess assay (nitrite production)

Fresh or frozen aliquots of conditioned media were analyzed for the presence of nitrite using the reagents provided in the Griess Reagent Kit according to the
manufacturer’s protocol. The reaction was started by the
addition of 20 μl of freshly prepared Greiss reagent to
wells containing 200 μl of deionized water and 50 μl of
sample media or standards (1–100 μM sodium nitrite
prepared in naïve media). Following a 30-min incubation
at room temperature in the dark, the absorbance at 548 nm
was measured using a microplate spectrophotometer.
Immunoblotting

Nuclear extracts of BV2 cells were isolated using the
NE-PER nuclear and cytoplasmic extraction reagent
(Thermo Scientific, Rockford, IL) according to the manufacturer’s protocol. Protein concentration was measured using DC Protein Assay (Bio-Rad, Hercules, CA).
Nuclear extracts were combined with a Laemmli sample
buffer (Bio-Rad) separated on 10% Mini-PROTEAN
TGX precast gels (Bio-Rad) at 200 V for 35 to 40 min,
then transferred to a polyvinylidene difluoride membrane (Bio-Rad) at 30 V over 24 h at 4°C. Following
transfer, the membrane was blocked with PBS/10%
Tween-20/5% dry milk for 30 min, then incubated overnight with anti-p50 antibody (sc-1190, Santa Cruz
Biotechnology, Dallas, TX) diluted 1:500 in PBS/10%
Tween-20/5% dry milk at 4 C. After three washes in
PBS/10% Tween-20, the membrane was incubated with
donkey anti-goat IgG antibody conjugated to HRP (sc2020, Santa Cruz Biotechnology) diluted 1:10,000 in
PBS/10% Tween-20/5% dry milk for 45 min at room
temperature. After 3 washes in PBS, the bands were visualized using SuperSignal West Femto Chemiluminescent
Substrate (Thermo Scientific). Chemiluminescence was
detected and saved as TIFF file images using a digital imaging system (VersaDoc MP 4000, Bio-Rad). For betaactin immunoblot, membranes were stripped using
Restore Western Blot Stripping Buffer (Thermo Scientific),
then incubated in anti-beta actin antibody (clone AC-74,
Sigma Aldrich) diluted 1:10,000 in PBS/10% Tween-20 for
3 h at room temperature, followed by washes and incubation in donkey anti-mouse IgG antibody conjugated to
HRP (sc-2314, Santa Cruz Biotechnology) diluted 1:10,000
in PBS/10% Tween-20. Beta-actin bands were visualized
using Immobilon Western Chemiluminescent HRP Substrate
(EMD Millipore, Billerica, MA). Chemiluminescence images
were analyzed on ImageJ to acquire relative density
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measurements. p50 band relative density measurements
were normalized to corresponding beta-actin relative
density measurements for each sample.
Chromatin immunoprecipitation (ChIP)

ChIP assays were performed using the Magna ChIP A/G
kit (Millipore, Billerica, MA) according to the manufacturer’s protocol. BV2 cells were plated in 15-cm culture
dishes overnight. Following treatment, cells were fixed in
freshly prepared formaldehyde (1% final concentration)
to cross-link protein and DNA. Cells were scraped and
re-suspended in protease inhibitor cocktail containing
buffer, lysed, then sheared by sonication. Genomic DNA
fragments were typically less than 500 bases in size; 10-μl
(2%) aliquots were set aside as input. Following overnight
immunoprecipitation with anti-acetylated histone 4 antibody (Millipore, Billerica, MA) or anti-NF-kappaB1 p50
antibody (sc-1190, Santa Cruz Biotechnology, Dallas, TX),
protein/DNA cross-linking was reversed and DNA purified prior to assay by PCR. Primers for PCR were designed
using Primer3 software [18] based on Nos2 gene and 5′
flanking sequences obtained from UCSC Genome
Bioinformatics [19]. Primer sequences are listed in Table 1.
PCR was performed using QuantiFast SYBR Green PCR
Kit (Qiagen, Valencia, CA) on a real-time PCR instrument
(Life Technologies, Carlsbad, CA). Percent input was calculated as the delta CT between input DNA and ChIP
DNA. Fold enrichment was calculated using the delta
delta CT method with normalization against either isotype
IgG ChIP DNA or a negative locus primer set.
DNase accessibility assay

DNase accessibility was measured in primary microglia
cells using the EpiQ Chromatin Analysis Kit (BioRad,
Hercules, CA) according to the manufacturer’s protocol.
Microglia were plated in 48-well culture plates at a density of 2 × 105 cells per well and incubated overnight prior
to treatment. Following treatment, chromatin was digested
in situ by incubation at 37°C for 15 min with 100 μl of
EpiQ chromatin buffer containing 2 μl DNase. Cells incubated with chromatin buffer without added DNase were
used as the undigested control. Addition of Stop Buffer
halted DNase activity and caused cells to detach during a
10-min incubation at 37°C. The resulting cell solutions
were combined with Lysis Solution and 100% ethanol,
mixing after each addition, and then transferred to the
supplied mini columns for isolation of DNA. Following
the application of alternating low and high stringency
wash solutions, purified genomic DNA was eluted using
DNA elution solution preheated to 70°C. Samples were
analyzed by quantitative PCR using primers designed to
amplify Nos2 and Tnf genes, promoters and flanking regions. Primers were designed using Primer3 software [18]
based on sequences obtained from UCSC Genome
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Table 1 PCR primer sequences
Primer ID

Forward

Reverse

Position relative to TSS

Nos2_ChIP

GGAGTGTCCATCATGAATGAG

CAACTCCCTGTAAAGTTGTGACC

−159 to −15

Nos2_ChIP2

CCAGAACAAAATCCCTCAGC

CTCATGCAAGGCCATCTCTT

−355 to −198

Nos2_ChIP3

AGCACAGCCCATCCACTATT

CGGAGCTCTCTGGCTTTCT

−551 to −359

Nos2_ChIP4

AAAGGCTTATGCCACCACAC

TTTTCTCAGTGGCATTCTCTCTC

−748 to −572

Nos2_ChIP5

AATTCCATGCCATGTGTGAA

TGATCCCTGAGTTTGGGCTA

−936 to −779

Nos2_ChIP6

TTGAGGCCACACACTTTTTG

TGACAGTGTTAGGGGAAAAGG

−1124 to −959

Nos2_ChIP7

TCACCACACCCAGCATTTTA

GGGAGATGGCTCAGTTGGTA

−1387 to −1188

Nos2_ChIP8

GGGTGTTGCCTGGATAAAGA

GTTCCAGGCTGGTGAGAGAT

−1654 to −1472

Nos2_ChIP9

AAGGGTTCCATTGTGACAAAC

CCCAATACTTGGGAAAGACG

−1855 to −1663

Nos2_ChIP10

CAGCCAAGCACTCCAATGTA

TTACAGCTACGCCTGCAACA

−2002 to −1880

Nos2_ChIP11

AAACTTCTCAGCCACCTTGG

TTCCCAAGCAGGAAGACACT

30 to 189

Nos2_ChIP12

AAACCAGGCTTTCCCTTCTC

TTGCAGAGAAGAAATCTGACCA

198 to 336

Nos2 a

GCTTCACTCAGCACAGCCCATCCAC

GCTAAACCACATACCCTGGCTTGCAG

−560 to −308

Nos2 b

GCCAGCCTCCCTCCCTAGTGAGTCC

GACCCTGGCAGCAGCCATCAGGTAT

−299 to −34

Nos2 c

CCTGCTTGGGAAAGCCCAGAAAACC

TGGGGCAGAGGGCACATCTCATAAA

178 to 462

TNF a

TCTAAATGGGACATCCATGGGGGAGA

TCCGTGAATTCCCAGGGCTGAGTTC

−673 to −424

TNF b

ACACCCTCCTGATTGGCCCCAGATT

CTTGCTGTCCTCGCTGAGGGAGCTT

−278 to 18

TNF c

CCCCTCCACACTCTCCTCCACCTTG

GGCAGAAGAGGCACTCCCCCAAAAG

191 to 464

GAPDH

AGTGCCCACTCCCCTTCCCAGTTTC

GAGGCCCAGCTACTCGCGGCTTTA

−178 to 98

Rhodopsin

CAGCCTGAGGCCACCAGACTGACAT

CACAGCGCAACTCCAGGCACTGAC

−268 to −6

Bioinformatics [19]. Primer sequences are listed in Table 1.
Delta CT was calculated as the difference in CT between
undigested and DNase digested samples. Low absolute
value delta CT corresponded to genomic DNA with high
nucleosome occupancy (heterochromatin), and high absolute value delta CT corresponded to genomic DNA with
low nucleosome occupancy (euchromatin). The promoter
region of the rhodopsin (Rho) gene, which is not expressed
in microglia, consistently showed no shift in CT between
the undigested and digested samples, indicating a heterochromatin structure. Conversely, the promoter region of
Gapdh, which is constitutively expressed, consistently
showed a shift in CT between the undigested and digested
samples, indicating an euchromatin structure (data not
shown). Percent chromatin accessibility was calculated
using the delta delta CT method using Rho gene promoter
as the reference region: (1- (2^(delta CT target gene - delta
CT Rho))) × 100.
Transfection with small interfering RNA (siRNA)

Primary murine microglia were transfected with siRNA
directed at HDAC3 or non-targeting siRNA (10 pmol/
1 × 105 cells; Dharmacon) using RNAi Max according to
the manufacturer’s protocol; 72 h following transfection,
cells were treated, and RNA was obtained using the
RNeasy Mini Kit (Qiagen). The efficiency of RNA knockdown was routinely 70–80% based on real-time RT-PCR.

EAE: induction and treatment

EAE was actively induced in 6 to 8-week-old (17 to 20 g)
C57BL/6 mice purchased from Harlan (Indianapolis, IN)
as previously described [20]. Mice were administered subcutaneous injection of 300 μg myelin oligodendrocyte
glycoprotein peptide (MOG35–55) in complete Freund’s adjuvant, followed by intraperitoneal injection of 300 ng pertussis toxin. Pertussis toxin injection was repeated 48 h
later. A control group of mice received complete Freund’s
adjuvant and pertussis toxin without MOG35–55. Groups
of mice were administered daily intraperitoneal injections
of either GW3965 or vehicle beginning day 8 post induction. GW3965 was dissolved in dimethyl sulfoxide
(DMSO), mixed 1 to 1 with PBS, and 50 μl of this mixture
containing 500 μg of GW3965 (or 25 to 30 mg/kg) was administered daily. Vehicle controls received 50 μl mixture
of DMSO and PBS (1:1) administered daily. Mice were
scored as follows: 0, no overt signs of disease; 1, limp tail
or hind limb weakness but not both; 2, limp tail and hind
limb weakness; 3, partial hind limb paralysis; 4, complete
hind limb paralysis; 5, moribund state. Primary clinical
outcome was the mean cumulative EAE score (sum of
clinical scores from induction until the day of sacrifice for
individual mice divided by the number of mice). Mice that
did not get sick were excluded from analysis. Following
euthanasia, animals underwent transcardiac perfusion
with up to 50 ml of normal saline using a rate-controlled
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and re-suspended in RPMI supplemented with Lglutamine, penicillin/streptomycin and 10% FCS. Cells were
then plated in 24-well plates and stimulated with PMA/
ionomycin/brefeldin A for 6 h as previously described [21].
Cells were fixed with 4% paraformaldehyde, permeabilized
with Perm/Wash Buffer (BD Biosciences, San Jose,
CA), then incubated with anti-CD3-PE-Cy5 (clone
17A2), anti-CD4-FITC antibody (clone GK1.5), antiinterleukin-17A-PE antibody (clone TC11-18H10) and
anti-interferon-γ-APC antibody (clone XMG1.2, BD

pump. Spines were dissected and cords were pushed out
of the column using hydraulic pressure applied through a
19-gauge needle and syringe filled with PBS.
Fluorescence-assisted cell-sorting (FACS) analysis

Following euthanasia, the cervical and axillary lymph
nodes and spleen were removed. Single cell suspensions
were prepared by grinding the tissue over a 70-μm sterile cell strainer using the rubber end of a syringe plunger
then washing with RPMI media. Cells were washed again
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Figure 1 LXR inhibits reactive nitrogen species production in cultured microglia. Primary murine microglia were pretreated with the LXR
agonist GW3965 (5 μM) with or without RXR agonist fluorobexarotene (0.1 μM) for 1 h then stimulated with LPS (10 ng/ml) or interferon-γ
(10 ng/ml) for 48 h. Real-time RT-PCR was used to measure RNA expression (relative expression). Nitrite was measured by Griess assay as an indicator of
nitric oxide production. IL-1β and TNF were measured by ELISA. A The effect of GW3965 (GW) or vehicle (VC, 0.05% DMSO) on LPS-induced RNA expression
of Nos2, IL1b and Tnf compared to unstimulated (unstim) cells. B The effect of GW3965 (GW) with or without fluorobexarotene (FB) on LPS-induced nitrite,
IL-1β and TNF production/release. C The effect of GW3965 (GW) with or without fluorobexarotene (FB) on interferon-γ-induced nitrite and TNF production/
release. Data are mean + SD. N = 6 independent experiments, except column A (N = 5). Kruskal-Wallis test: *< 0.05, **< 0.001.
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Biosciences) for 30 min. FACS data were acquired on a
FACSCalibur (BD Biosciences) and analyzed using
FlowJo software (FLOWJO, Ashland, OR). FSC vs. SSC
plots were used to gate on live cells. CD3 vs. CD4 plots
were used to gate on CD3 + CD4+ cells. Interleukin-17
vs. interferon-γ plots were used to gate on interleukin17 positive, interferon-γ positive and double-positive
cells.
Statistical analysis

Mann–Whitney was used for two group comparisons.
Kruskal-Wallis test with Dunn’s post-hoc analysis
was used for multiple comparisons. Statistical analysis was performed using Prism software (GraphPad,
La Jolla, CA).

Results
LXR inhibits reactive nitrogen species production in
cultured microglia

The synthetic LXR agonist GW3965 was used to study
the effect of LXR activation in primary cultures of murine microglia. Stimulation with LPS resulted in activation of microglia as evidenced by increased nitric oxide,
IL-1β and TNF production. The addition of GW3965 to
culture resulted in reduced Nos2 transcript and significant reduction in LPS-induced nitric oxide (nitrite) production/release (Figure 1A and B). The presence of RXR
agonist fluorobexarotene potentiated the inhibitory effect of LXR agonist on LPS-induced nitric oxide production/release. LXR activation also had a consistent partial
inhibitory effect on LPS-induced IL-1β transcriptional
activity and production/release, which was potentiated
by the presence of RXR agonist. The effect of LXR agonist on interferon-γ-induced Nos2 activation was less reliable (Figure 1C). Furthermore, we did not observe a
reliable effect of LXR activation on microglial production of TNF.
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LXR activation is associated with histone deacetylation
and inhibition of p50 binding at the Nos2 promoter

To investigate the mechanism of LXR-dependent inhibition of LPS-induced microglial activation, the effect of
LXR activation NF-kappaB signaling was examined. Nuclear extracts were isolated from microglial cell line BV2
to detect nuclear translocation of NF-kappaB1 p50 by
immunoblotting. Figure 2 shows that the levels of nuclear p50 are increased following LPS stimulation, indicating nuclear translocation of NF-kappaB1 p50.
Pretreatment with the LXR agonist GW3965 did not
reduce the levels of nuclear p50 in the LPS-stimulated
cells. The results indicate that LXR activation does
not inhibit nuclear translocation of NF-kappB1 or
otherwise reduce the levels of nuclear NF-kappaB1.
Previous studies reported that LXR associates with histone deacetylase (HDAC) 3 via the LXR-NCoR complex,
suggesting that the transcriptional repression by the
LXR-NCoR complex involves histone modification [22].
To examine the effect of LXR activation on histone
modification at the Nos2 promoter and its impact on
LPS-induced NF-kappaB signaling [23], ChIP was performed on microglial cell line BV2 using antibodies specific to acetylated histone 4 and NF-kappaB1 p50. Figure 3
shows results from the promoter “tiling” ChIP experiment
using primers that collectively amplify a ~2 kilobase region upstream of the Nos2 gene. Following LPS stimulation of BV2 cells, a peak of histone 4 acetylation was
detected at −551 to −359 bases upstream of the Nos2 transcriptional start site (Figure 3A). The peak of NF-kappaB1
p50 binding was detected at −159 to −15 bases upstream
of the Nos2 transcriptional start site upon LPS stimulation
(Figure 3B). To investigate the relationship between histone acetylation and NF-kappaB1 p50 binding at the Nos2
promoter, cells were pretreated with C646, an inhibitor of
histone acetyltransferase [24]. Inhibition of histone acetyltransferase resulted in reduced NF-kappaB1 p50 binding
at the Nos2 promoter, suggesting that histone acetylation

Figure 2 LXR activation does not inhibit nuclear translocation of NF-kappaB1 p50. Nuclear extracts from microglial cell line BV2 were
isolated following 3 h LPS (10 ng/ml) stimulation. Cells were pretreated with either LXR agonist GW3965 (5 μM) or vehicle (0.05% DMSO). NF-kappaB1
p50 was detected by immunoblotting. Relative density measurements of the p50 bands were normalized to relative beta-actin density. Left figure
shows p50 and corresponding beta-actin immunoblots for unstimulated (VC), vehicle pretreated/LPS stimulated (VC/LPS) and GW3965 pretreated/LPS
stimulated (GW/LPS) samples from three independent experiments (“Expt”). Right figure shows a summary plot of the normalized relative density
measurements of the p50 bands for each condition.
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Figure 3 Stimulation of microglia results in histone acetylation
and NF-kappaB1 p50 binding at the Nos2 promoter. Chromatin
immunoprecipitation (ChIP) was performed on microglial cell line
BV2 following 3 h LPS (10 ng/ml) stimulation with or without
histone acetyltransferase inhibitor C646. A Acetylated histone 4
(AcH4) ChIP on LPS-stimulated BV2. AcH4 ChIP using primers spanning
2 kb upstream of Nos2 transcriptional start site (TSS) showed that the
peak of histone 4 acetylation is detected by primers amplifying −551
to −359 bases upstream of Nos2. Mean + SD. N = 3. B NF-kappaB1 p50
ChIP on LPS-stimulated BV2. p50 ChIP using primers spanning 2 kb
upstream of Nos2 TSS demonstrated the peak of p50 binding at
−159 to −15 bases upstream of Nos2. Mean + SD. N = 3. C The
effect of pretreatment with histone acetyltransferase inhibitor C646
(C646/LPS) on NF-kappaB1 p50 binding detected by ChIP at the
Nos2 promoter compared to unstimulated (VC) and vehicle treated
(VC/LPS) cells. Data shown for primers amplifying −159 to −15
bases upstream of Nos2 TSS: three independent
experiments (Expt).

DNase accessibility assay defines an inducible
nucleosome depleted region in the Nos2 promoter, but
DNase accessibility is not altered by LXR activation

We next sought to determine the scale of epigenetic
modification involved in LXR-dependent Nos2 repression. Specifically, we asked whether or not LXRdependent repression involves alteration in nucleosome
occupancy over the Nos2 promoter. We used in situ
DNase digestion followed by quantitative PCR to identify
regions of genomic DNA with high nucleosome occupancy or heterochromatin and regions of genomic DNA
with low nucleosome occupancy or euchromatin. In unstimulated primary murine microglia, the proximal 5′
flanking region of the Nos2 gene showed low DNase accessibility, indicating heterochromatin structure (Figure 5B).
Upon LPS stimulation, however, DNase accessibility of the
Nos2 promoter region increased significantly, indicating inducible nucleosome depletion and transition to euchromatin structure. In contrast, the proximal 5′ flanking region of
the Tnf gene showed high DNase accessibility in both the
unstimulated and LPS-stimulated states, indicating constitutive euchromatin structure of the Tnf promoter
(Figure 5B). To test whether or not LXR-dependent Nos2
repression involves alteration in nucleosome occupancy,
DNase accessibility was assessed in microglia pretreated
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Figure 4 LXR activation is associated with histone deacetylation and inhibition of p50 binding at the Nos2 promoter. A AcH4 ChIP at
the Nos2 promoter for LPS-stimulated BV2 cells pretreated with 5 μM GW3965 (GW/LPS) compared to unstimulated (VC) and vehicle
pretreated (VC/LPS) cells. Data shown for primers amplifying −551 to −359 upstream of Nos2. B NF-kappaB1 p50 ChIP at the Nos2 promoter
for LPS stimulated BV2 cells pretreated with 5 μM GW3965 (GW/LPS) compared to unstimulated (VC) and vehicle pretreated (VC/LPS) cells. Data
shown for primers amplifying −159 to −15 bases upstream of Nos2. C Microglial cell line BV2 were pretreated with 1 μM GW3965 (GW), HDAC
inhibitor trichostatin A (TSA, 10 nM) or vehicle (VC, 0.1% DMSO) for 1 h, then stimulated with LPS (10 ng/ml). Nitric oxide (nitrite) production
was measured by Griess assay. Data are mean + SD. N = 4 independent experiments. D Primary murine microglia were transfected with HDAC3
siRNA (HDAC3 siR) or non-targeting siRNA (NT siR); 72 h following transfection, cells were pretreated with 1 μM GW3965 (GW) or vehicle (VC,
0.05% DMSO) for 1 h followed by stimulation with LPS (10 ng/ml). Nos2 gene expression (relative expression) was determined by real-time
RT-PCR. Data are mean + SD. N = 3 independent experiments.

with GW3965. The addition of LXR agonist had no effect
on DNase accessibility at the Nos2 promoter (Figure 5C).
LXR activity is reduced in the setting of CNS inflammation

The inhibitory effect of LXR on microglial Nos2 indicates a potential role for LXR in modulating CNS inflammation. LXR activity during CNS inflammation,
however, has not previously been described. We used
EAE as an animal model of CNS inflammation. To assess LXR levels and activity, RNA was isolated from
the spinal cords of EAE and control mice at 12 to
14 days post-induction (peak of clinical disease). RNA
expressions of Lxra, Lxrb and the LXR-dependent
genes Abca1, Abcg1 and Apoa1 were determined by
real-time RT-PCR. Lxra, Lxrb, Abcg1and Apoa1 expressions were significantly reduced in EAE compared

to control animals, indicating diminished LXR activity
in the setting of EAE (Figure 6). Abca1 levels were not
significantly altered (data not shown). Nos2, Il1b, Tnf
and Il6 levels were significantly elevated in EAE
compared to control animals, indicating the activation
of proinflammatory genes during EAE (Figure 6).
LXR activation is associated with delay in onset of EAE
and induction of reverse cholesterol transport genes in
the CNS

Animals were administered GW3965 during the effector phase of EAE to determine the effect of LXR
activation on CNS inflammation. Following active induction of EAE, animals were administered daily intraperitoneal injections of GW3965 (25 to 30 mg/kg)
or vehicle (DMSO) beginning at day 8 post-induction.
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Figure 5 DNase accessibility assay defines an inducible nucleosome-depleted region on the Nos2 promoter, but DNase accessibility is
not altered by LXR activation. Cultured microglia were subjected to in situ chromatin digestion by DNase, followed by quantitative PCR.
The shift in CT values between digested and undigested chromatin reflected nucleosome occupancy. DNase accessibility (% chromatin
accessibility) was quantified using the delta delta CT calculation, normalizing to the Rho promoter. Low % chromatin accessibility indicated
high nucleosome occupancy and a high % chromatin accessibility indicated nucleosome depletion. A Schematic representation of
genomic DNA regions amplified following DNase digestion relative to transcription start site (right-angle arrow). B The proximal 5′ region
flanking the Nos2 gene (b) showed low accessibility in the unstimulated state and significantly higher DNase accessibility following LPS
stimulation. The proximal 5′ region flanking the Tnf gene (b) showed constitutive high DNase accessibility. Data are mean + SD. N = 4
independent experiments. *< 0.05, Mann–Whitney. C DNase accessibility is not altered at the Nos2 promoter in the presence of LXR
agonist GW3965 (5 μM, GW/LPS). Data for Tnf promoter are also shown. Data are mean + SD. N = 4 independent experiments.

Animals administered GW3965 had significantly reduced cumulative clinical scores compared to vehicle
treated animals at day 14 post induction (5.1 ± 1.4 vs.
10.4 ± 6.3, p = 0.049), indicating delayed onset of clinical disease in LXR agonist treated animals. Analysis
of a subset of animals treated for up to 21 days post
induction showed that at later time points the disease
severity was comparable between GW3965 and vehicle treated animals (Figure 7A). These results suggest that LXR activation impacts the acute, but not
chronic, phase of EAE.

The induction phase of EAE involves peripheral
lymphocyte activation, whereas the effector phase of
EAE involves the establishment of CNS inflammation. A
previous study indicated that LXR influences Th17
lineage differentiation, which is critical to induction of
EAE [14]. To assess the effect of LXR activation on
peripheral lymphocytes during EAE, intracellular
interleukin-17 and interferon-γ were detected in CD4 + T
lymphocytes obtained from lymph nodes and spleen to
identify Th1 and Th17 cells by flow cytometry. There were
no significant differences between LXR and vehicle treated
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Figure 6 LXR activity is reduced in the setting of CNS inflammation. Total RNA was isolated from the spinal cord of experimental allergic
encephalomyelitis (EAE) and control mice 12 to 14 days post-induction. RNA levels (relative expression) for Lxra, Lxrb, Abcg1, Apoa1, Nos2, Il1b, Tnf
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animals with respect to the frequency of Th1 and Th17
cells in the lymph node at day 14 post induction
(Figure 7B). Similar results were obtained for splenic T
cells (data not shown).
To assess CNS LXR activity and CNS inflammation,
RNA was isolated from spinal cords of EAE and vehicle
treated animals to measure LXR-dependent gene expression. The LXR-dependent genes Abca1 and Abcg1 were
significantly increased in GW3965 treated EAE animals

compared to vehicle treated animals, indicating increased expression of genes involved in reverse cholesterol transport. RNA expressions of inflammatory genes
were also measured. Neither the Nos2 nor the Il1b gene
expressions were significantly altered by the administration of LXR agonist GW3965 (Figure 7C). Tnf expression was also not significantly altered by LXR agonist
administration (data not shown). Thus, the administration of LXR agonist had a more reliable impact on the
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Figure 7 LXR activation is associated with delay in onset of EAE and induction of reverse cholesterol transport genes in the CNS.
Animals induced to undergo EAE were administered daily intraperitoneal injections of GW3965 (GW) or vehicle (VC) beginning day 8 postinduction (arrow). Animals were killed at day 14 to obtain lymph nodes, spleen and spinal cord. All animals received daily injections up to 14 days
post induction (N = 19 for the GW group, N = 22 for VC group). A subset of animals (N = 9 for the GW group, N = 12 for the VC group) received
daily injections up to 21 days post induction. A Clinical score (mean ± SE) of EAE over time for GW and VC treated animals. B The frequency
interleukin-17A positive (IL17+) and/or interferon-γ positive (IFNg+) CD3 + CD4+ T cells in the lymph nodes (cervical and axillary) of GW and
vehicle VC treated animals at day 14 post induction. C CNS expression of reverse cholesterol transport genes (Abca1 and Abcg1) and inflammatory
genes (Nos2 and Il1b) for VC and GW treated animals. Line and error bars indicate median with interquartile range. Mann–Whitney test
of significance.

activation of LXR-dependent genes involved in reverse
cholesterol transport than on repression of inflammatory
genes, including Nos2, in the context of EAE.

Discussion
Persistent microglial activation has been implicated in
the pathogenesis of a number of neuroinflammatory and
neurodegenerative disorders [2]. Reactive oxygen species, reactive nitrogen species and inflammatory cytokines have been identified as potentially deleterious
products of chronic microglial activation in these disorders, leading to oxidative stress and mitochondrial

dysfunction [3]. Mechanisms that inhibit microglial activation, therefore, have the potential to modulate deleterious effects of microglial response in neuroinflammatory
and neurodegenerative diseases.
In this report, we confirmed that the activation of the
nuclear receptor LXR modifies microglial response to
the inflammatory mediator LPS in vitro. In particular,
LXR activation inhibited microglial production of the reactive nitrogen species nitric oxide. We observed partial
inhibition of IL-1β production. LXR-dependent inhibition of nitric oxide and IL-1β production corresponded
to reductions in Nos2 and Il1b expressions. The effect of

Secor McVoy et al. Journal of Neuroinflammation (2015) 12:27

LXR activation on TNF production was less reliable.
These results are in agreement with previous studies
that identified Nos2 and Il1b, but not Tnf, as LXRrepressed genes [25]. The effect of LXR activation on
microglial response to interferon-γ was less reliable.
There was a trend to decreased nitric oxide production
by microglia pretreated with LXR agonist that did not
reach statistical significance in the setting of interferon-γ
stimulation, possibly indicating a smaller magnitude of
LXR-dependent inhibition. Stimulus-specific differences
in LXR-dependent inhibition are likely to be important
in neuroinflammatory diseases such as multiple sclerosis,
where both Toll-like receptor and interferon-γ signaling
have been reported [26-29].
LXR activation did not inhibit nuclear translocation of
NF-kappaB1 p50, indicating that the mechanism of
LXR-dependent repression of inflammatory genes does
not involve limiting the amount of NF-kappaB transcription factor available for binding DNA in the nucleus. A
previous study showed that ligand-dependent transcriptional repression by LXR involves post-translational modification by SUMOylation and subsequent stabilization of
the LXR-NCoR complex on the promoters of target genes
[7]. Histone deacetylase (HDAC) and BRG1 are components of the NCoR complex, suggesting that the mechanism of LXR-dependent transcriptional repression involves
epigenetic modification [22,30]. We detected peak of LPSinduced NF-kappaB1 p50 binding at −159 to −15 bases
upstream of the Nos2 transcription start site, which corresponds to the previously reported proximal enhancer
cluster on the Nos2 promoter [31]. In addition, we detected histone 4 acetylation upstream of the Nos2 gene in
response to LPS stimulation of microglia, with the peak of
histone 4 acetylation detected between −551 to −359 bases
upstream of the Nos2 transcriptional start site. Thus, the
peaks of NF-kappaB1 p50 binding and histone 4 acetylation are within 2 to 3 nucleosome distances of each other
upstream of the Nos2 gene. Inhibition of histone acetyltransferase reduced NF-kappaB1 p50 binding on the Nos2
promoter, suggesting that histone acetylation results in
promoter configuration that permits p50 occupancy. Both
histone 4 acetylation and p50 binding were partially inhibited by LXR activation, providing additional evidence for a
mechanistic link between histone acetylation and NFkappaB1 p50 binding on the Nos2 promoter. The addition
of HDAC inhibitor or HDAC3 siRNA partially reversed
the LXR-dependent repression of nitric oxide production,
indicating that LXR-dependent gene repression may be
vulnerable to HDAC inhibitors. The interpretation of
HDAC inhibitor/siRNA experiments are confounded by
that fact that the addition of HDAC inhibitor alone or
HDAC3 siRNA alone resulted in increased nitric oxide
production or Nos2 expression above baseline, indicating
that HDAC activity exerts basal repression of Nos2
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transcription independent of LXR ligand. DNase accessibility assay indicated that unlike the Tnf promoter region,
which demonstrated constitutive nucleosome depletion,
the Nos2 promoter appears to be an activation-dependent,
inducible nucleosome-depleted region in the microglia. In
the resting state, the Nos2 promoter region showed high
nucleosome occupancy. Stimulation with LPS resulted in
depletion of nucleosome on the Nos2 promoter, indicating
a shift to euchromatin. Addition of LXR agonist did not
alter DNase accessibility at the Nos2 promoter. Together,
these data suggest that the mechanism of LXR-dependent
Nos2 repression involves histone deacetylation that likely
alters the local transcription factor access to response elements without a change in the regional nucleosome
occupancy.
A key question addressed by this study is whether or
not LXR activation can regulate CNS inflammation. A
related question is whether or not endogenous LXR activity is a physiologic regulator of CNS inflammation. A
previous study reported that LXR knockout animals
showed increased clinical disease severity during EAE
that was explained by the loss of inhibitory influence on
lymphocyte Th17 lineage differentiation [14]. Thus, LXR
appears to exert physiologic control over peripheral
lymphocyte activation during the induction phase of
EAE. In the CNS compartment, however, we found reduced expression of LXR and LXR-dependent genes, indicating that the endogenous LXR activity is, in fact,
diminished in the context of CNS inflammation. The reduction in LXR and LXR-dependent genes in the CNS is
consistent with previous reports of LXR expression in
several other organs. In hepatocytes, renal cells and adipocytes, induction of acute phase response by LPS, TNF
and/or IL-1β is associated with reduction in nuclear receptor levels including LXR [32-34]. Thus, inflammatory
cytokine-induced suppression of LXR expression also
appears to occur in the CNS.
The administration of LXR ligand, nevertheless, partially reversed the diminished LXR activity during
EAE. LXR ligand administration increased the expression of LXR-dependent genes involved in reverse cholesterol transport including Abca1 and Abcg1 above
those in vehicle treated animals, indicating upregulation of LXR activity in the CNS. The administration of
LXR ligand had a less reliable effect with respect to repression of inflammatory genes. In particular, we did
not see significant repression of Nos2 expression in
the spinal cord of EAE animals following LXR agonist
administration. LXR agonist delayed the onset of clinical disease in EAE, but did not impact the severity of
clinical disease at later time points, likely reflecting
the failure of LXR activation to establish repression of
CNS inflammatory genes in EAE. Several explanations
are possible. We found a more reliable inhibitory
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effect of LXR on LPS-induced microglial activation
compared to interferon-γ-induced microglial activation. Therefore, CNS inflammatory conditions such as
EAE and MS where both Toll-like receptor and
interferon-γ signaling are detected may be less responsive to inhibitory action of LXR [26,27]. Alternatively,
the threshold for transcriptional activation and transcriptional repression by LXR may be different in the
context of CNS inflammation. Whereas genes involved
in reverse cholesterol transport are coordinately regulated by LXR transcriptional activation involving exchange of NCoR for NCoA, the antiinflammatory
effects of LXR are under SUMOylation-dependent
transcriptional repression [35]. There is evidence that
the activation and repression functions of LXR can be
uncoupled [36]. Although we found no change in the
frequency of Th17 cells at day 14 post induction, it remains possible that the delay in onset of EAE clinical
disease in LXR agonist treated animals might reflect
an inhibitory effect of LXR activation on peripheral
lymphocytes.
There are several limitations to the study. Analysis of
gene expression was performed on spinal cord homogenates, representing multiple cell types. It is possible that
analysis of isolated microglia/macrophage might have
detected a statistically significant effect of LXR activation
on inflammatory gene expression. However, LXRdependent repression of inflammatory genes has been
reported in multiple cell types including astrocytes [37]
and therefore would have been expected to have broader
antiinflammatory effects. This study differs from previous studies testing the effect of LXR agonist in EAE with
respect to either onset of drug administration or the specific drug administered. Two previous studies examined
the effect of LXR agonist administered during the induction phase [14,38], whereas LXR agonist was administered during the effector phase in the current study. A
previous study tested a different LXR agonist (T091317)
during the effector phase of EAE [38]. T0901317 has
turned out to be a rather non-specific LXR agonist, with
additional activity toward pregnane X receptor and
farnesoid X receptor, not seen in GW3965 [39,40].

Conclusions
In conclusion, LXR activation inhibits microglial Nos2
expression and nitric oxide production, in part by
histone deacetylation leading to impaired NF-kappaB1
p50 binding on the Nos2 promoter. Endogenous LXR activity is diminished in the setting of CNS inflammation.
Administration of exogenous LXR agonist delays the onset of clinical disease and reverses the diminished LXR
activity with respect to genes involved in reverse cholesterol transport, but does not significantly inhibit CNS
inflammatory genes in EAE.
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